|
U.S. doctors find themselves navigating political landmines as conservative views criticize recommendations, science |
mike kraft |
Group Post |
10/04/23 |
|
U.S. Doctors seek more information on Paxlovid prescribing amid Covid-19 rebound concerns |
mike kraft |
Group Post |
07/07/22 |
|
U.S. dropped from list of COVID-safe countries for travel to Europe |
mike kraft |
Group Post |
08/30/21 |
|
U.S. East Coast cities from NYC to DC and south are sinking--new studies |
mike kraft |
Group Post |
01/03/24 |
|
U.S. emerges as outlier on Covid measures as Biden faces political headwinds |
mike kraft |
Group Post |
12/02/21 |
|
U.S. exceeds 400,000 coronavirus deaths |
mike kraft |
Group Post |
01/19/21 |
|
U.S. expanding airport nasal swabbing to Chicago and Miami |
mike kraft |
Group Post |
03/13/24 |
|
U.S. expected to advise COVID booster shots for most Americans at 8 months |
mike kraft |
Group Post |
08/17/21 |
|
U.S. expected to provide additional 500 million Pfizer-BioNTech doses to 100 nations over the next year |
mike kraft |
Group Post |
06/09/21 |
|
U.S. Experts expect subvariants to cause ‘substantial’ summer cases of COVID-19 |
mike kraft |
Group Post |
06/27/22 |
|
U.S. extends COVID vaccine requirements for non-citizens at land borders |
mike kraft |
Group Post |
04/21/22 |
|
U.S. extends public health emergency status for COVID |
mike kraft |
Group Post |
01/11/23 |
|
U.S. F.D.A. advisers recommend updated boosters that target Omicron variants |
mike kraft |
Group Post |
06/28/22 |
|
U.S. faces a double coronavirus surge as omicron advances |
mike kraft |
Group Post |
12/16/21 |
|
U.S. FDA cleares the first home flu and Covid test — but its maker just declared bankruptcy |
mike kraft |
Group Post |
02/27/23 |
|
U.S. FDA advisers recommend Pfizer/BioNTech COVID-19 vaccine for children |
mike kraft |
Group Post |
10/26/21 |
|
U.S. FDA aims to decide on strain selection for COVID boosters by June |
mike kraft |
Group Post |
04/07/22 |
|
U.S. FDA approves antibody to protect infants from RSV |
mike kraft |
Group Post |
07/18/23 |
|
U.S. FDA approves COVID preventive Pemgarda for immunocompromised persons |
mike kraft |
Group Post |
03/26/24 |
|
U.S. FDA approves first RSV vaccine, a long-sought scientific achievement |
mike kraft |
Group Post |
05/03/23 |
|
U.S. FDA approves Gilead's COVID-19 drug for young children |
mike kraft |
Group Post |
04/25/22 |
|
U.S. FDA approves RSV monoclonal antibody for infants, young children at high risk |
mike kraft |
Group Post |
07/18/23 |
|
U.S. FDA authorization for updated Covid-19 boosters for younger ages could come as soon as early October |
mike kraft |
Group Post |
09/29/22 |
|
U.S. FDA authorizes first COVID-19 shot for young kids |
mike kraft |
Group Post |
10/29/21 |
|
U.S. FDA authorizes Moderna's COVID-19 vaccine for emergency use |
mike kraft |
Group Post |
12/18/20 |
|
U.S. FDA authorizes Moderna, Pfizer updated COVID boosters for 6 months old |
mike kraft |
Group Post |
12/08/22 |
|
U.S. FDA authorizes Novavax's COVID vaccine as booster for adults |
mike kraft |
Group Post |
10/19/22 |
|
U.S. FDA authorizes Pfizer/BioNTech booster for 16- and 17-year-olds |
mike kraft |
Group Post |
12/09/21 |
|
U.S. FDA authorizes spring covid booster shots for older adults and the immunocompromised |
mike kraft |
Group Post |
04/18/23 |
|
U.S. FDA authorizes use of AstraZeneca COVID-19 antibody cocktail |
mike kraft |
Group Post |
12/08/21 |
|
U.S. FDA clears updated COVID boosters for kids as young as 5 |
mike kraft |
Group Post |
10/12/22 |
|
U.S. FDA cuts gap for Moderna COVID-19 booster dose to 5 months |
mike kraft |
Group Post |
01/07/22 |
|
U.S. FDA gearing up for rapid review of potential COVID-19 booster shots |
mike kraft |
Group Post |
02/05/21 |
|
U.S. FDA grants full approval to Pfizer COVID vaccine for ages 12-15 |
mike kraft |
Group Post |
07/08/22 |
|
U.S. FDA has not seen possible side-effects of COVID shots being studied in EU |
mike kraft |
Group Post |
08/12/21 |
|
U.S. FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, increased cases |
mike kraft |
Group Post |
06/17/24 |
|
U.S. FDA OKs another Pfizer, Moderna COVID booster for 50 and up |
mike kraft |
Group Post |
03/29/22 |
|
U.S. FDA panel narrowly backs Merck's at-home COVID-19 pill |
mike kraft |
Group Post |
11/30/21 |
|
U.S. FDA panel narrowly backs Pfizer RSV vaccine for older adults |
mike kraft |
Group Post |
03/01/23 |
|
U.S. FDA panel recomends retiring original Covid vaccine and using newer versions |
mike kraft |
Group Post |
01/27/23 |
|
U.S. FDA panel recommends booster shots for Johnson & Johnson vaccine |
mike kraft |
Group Post |
10/15/21 |
|
U.S. FDA panel to advise on whether — and how — Covid vaccines should be updated |
mike kraft |
Group Post |
06/27/22 |
|
U.S. FDA panel unanimously votes in favor of RSV antibody treatment for infants |
mike kraft |
Group Post |
06/08/23 |
|
U.S. FDA proposes major shift to annual COVID vaccine strategy--one shot annually |
mike kraft |
Group Post |
01/23/23 |
|
U.S. FDA recalls supplement claiming COVID-related health benefits |
mike kraft |
Group Post |
03/10/23 |
|
U.S. FDA removes COVID test requirements before prescribing Pfizer, Merck treatment pills |
mike kraft |
Group Post |
02/01/23 |
|
U.S. FDA reportedly wil allow mixing and matching of COVID-19 boosters |
mike kraft |
Group Post |
10/18/21 |
|
U.S. FDA says robust safety data needed before COVID-19 vaccine approval for kids |
mike kraft |
Group Post |
09/10/21 |
|
U.S. FDA settles lawsuit over its criticisms of using ivermectin to counter COVID |
mike kraft |
Group Post |
03/29/24 |
|
U.S. FDA staff says Moderna did not meet all criteria for COVID-19 boosters |
mike kraft |
Group Post |
10/12/21 |
Recent Comments